Clinical Trials Logo

Hyperuricemia clinical trials

View clinical trials related to Hyperuricemia.

Filter by:

NCT ID: NCT02416167 Completed - Hyperuricemia Clinical Trials

Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is confirmatory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 12 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 8 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.

NCT ID: NCT02371421 Completed - Hyperuricemia, Gout Clinical Trials

Genetics of Hyperuricemia Therapy in Hmong

GOUT-H
Start date: June 2014
Phase:
Study type: Observational

To pursue this objective, we will be measuring uric acid at baseline and post 14 days of twice daily allopurinol therapy in 30 Hmong participants with documented gout or hyperuricemia and known genotype for key renal transporters of uric acid.

NCT ID: NCT02344862 Completed - Hyperuricemia Clinical Trials

Study of FYU-981 in Hyperuricemia With or Without Gout

Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 8 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 4 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.

NCT ID: NCT02338323 Completed - Clinical trials for Chronic Kidney Disease

Compare the Renal Protective Effects of Febuxostat and Benzbromarone

Start date: January 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether febuxostat and benzbromarone could protect renal function, and which one could be better.

NCT ID: NCT02338128 Completed - Hyperuricemia Clinical Trials

The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients

Start date: January 2015
Phase:
Study type: Observational

The purpose of this study is to determine whether Febuxostat could protect cardiovascular function of peritoneal dialysis patients by lowering serum uric acid.

NCT ID: NCT02327754 Completed - Clinical trials for Diabetic Nephropathy

Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout

UPWARD
Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the effect of topiroxostat on urinary albumin excretion and the safety in patients with early stage diabetic nephropathy and hyperuricemia with or without gout. Participants are randomized to placebo (n=20) or topiroxostat (n=40) for 28 weeks. The investigational drugs for this study are supplied by FUJI YAKUHIN CO., LTD.

NCT ID: NCT02317861 Completed - Clinical trials for Gout and Asymptomatic Hyperuricemia

A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to explore the pharmacodynamics (PD), pharmacokinetics (PK), safety, and tolerability of multiple doses of RDEA3170 administered in combination with febuxostat compared to RDEA3170 administered alone and febuxostat administered alone in Japanese adult male subjects with gout or asymptomatic hyperuricemia.

NCT ID: NCT02290210 Completed - Gout Clinical Trials

Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients

Start date: July 24, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia

NCT ID: NCT02252835 Completed - Gout Clinical Trials

Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

Start date: August 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate pharmacokinetics, pharmacodynamics, safety and potential for drug-drug interaction of arhalofenate when combined with febuxostat in adult population with gout.

NCT ID: NCT02213562 Completed - Hyperuricemia Clinical Trials

Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia

Start date: July 2014
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the efficacy and dose-dependency of chrysanthemum flower oil in suppressing serum uric acid.